Article
Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Clinical lung cancer - 1 Nov 2013
Dong Xiaopeng, Zhao Xiaogang, Hao Yingtao, Wei Yucheng, Yin Qiuwei, Du Jiajun
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR)-targeted therapy has shown a favorable efficacy in patients with non-small-cell lung cancer (NSCLC). Conversely, K-RAS mutations were reported to have an adverse effect on the survival of patients with NSCLC. These studies suggest that the tumor biology of patients with EGFR or K-RAS mutations is different from that of patients with wild-type mutations....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.